Determination of Lisdexamfetamine in Human Plasma by LC-MS/MS Method
Authors:
- Alex A. R. SilvaASAlex A. R. Silva
- Lilia L. D. CoelhoLCLilia L. D. Coelho
- Karen Y. Sánchez-LuquezKSKaren Y. Sánchez-Luquez
- Pedro H. D. GarciaPGPedro H. D. Garcia
- Renata BoldinRBRenata Boldin
- Anne M. R. SilveiraASAnne M. R. Silveira
- Marcia A. AntonioMAMarcia A. Antonio
- Andreia M. PorcariAPAndreia M. Porcari
- Patrícia O. CarvalhoPCPatrícia O. Carvalho
- 1 January 2025
- journal article
- research article
- Published by Sociedade Brasileira de Quimica (SBQ) in Journal of the Brazilian Chemical Society
- Vol. 36 (4)
Abstract
Lisdexamfetamine is a prodrug that is converted to d-amphetamine in the body, mainly used to treat attention deficit hyperactivity disorder in children and adults. Its mechanism involves the enhancement of neurotransmitters such as norepinephrine and dopamine, which are critical for attention and behavioral regulation. With the upcoming patent expiration of Vyvanse®, bioanalytical methods for the quantification of lisdexamfetamine in plasma are needed for use in pharmacokinetic studies. In this work, we developed and validated a sensitive bioanalytical method using liquid chromatography-tandem mass spectrometry (LC-MS/MS) for lisdexamfetamine quantification in human plasma. The method developed was performed for 4 min per sample and using the concentration range of 0.3-100 ng mL-1. Intra-batch, inter-batch and instrument reproducibility, the precision was lower than 10%. The results demonstrated that the method is rapid, sensitive, robust, and suitable for pharmacokinetic studies.Keywords
This publication has 29 references indexed in Scilit:
- Sensitive LC–MS/MS method for quantification of rivaroxaban in plasma: Application to pharmacokinetic studiesBiomedical Chromatography, 2021
- Determination of amlodipine, indapamide and perindopril in human plasma by a novel LC–MS/MS method: Application to a bioequivalence studyBiomedical Chromatography, 2020
- Lisdexamfetamine and amphetamine pharmacokinetics in oral fluid, plasma, and urine after controlled oral administration of lisdexamfetamineBiopharmaceutics & Drug Disposition, 2020
- A phase 1, randomized, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjectsNeuropsychopharmacology Reports, 2019
- Novel determination of sofosbuvir and velpatasvir in human plasma by UPLC–MS/MS method: Application to a bioequivalence studyBiomedical Chromatography, 2018
- Method validation and determination of lisdexamfetamine and amphetamine in oral fluid, plasma and urine by LC–MS/MSBiomedical Chromatography, 2016
- Pharmacokinetics of Coadministered Guanfacine Extended Release and Lisdexamfetamine DimesylateDrugs in R&D, 2013
- An Open-Label Investigation of the Pharmacokinetic Profiles of Lisdexamfetamine Dimesylate and Venlafaxine Extended-Release, Administered Alone and in Combination, in Healthy AdultsClinical Drug Investigation, 2013
- Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: A single-dose, randomized, open-label, crossover studyClinical Therapeutics, 2010
- Lisdexamfetamine Dimesylate and Mixed Amphetamine Salts Extended-Release in Children with ADHD: A Double-Blind, Placebo-Controlled, Crossover Analog Classroom StudyBiological Psychiatry, 2007